The U.S. is showing signs of targeting China's domestic surveillance and the tech supporting it.Technologyread more
Pro-EU parties are set to hold onto two-thirds of the seats at the EU Parliament.Europe Politicsread more
The projected result comes shortly after Conservative Party leader Theresa May announced her resignation as prime minister on Friday morning.Europe Politicsread more
A Beijing decision to rapidly and sharply cut its excessive and unsustainable trade surplus with the U.S. would change for the better the bilateral relationship, writes...World Economyread more
Former Apple CEO John Sculley says this skill is vital to all great business leadership.Successread more
Prime Minister Narendra Modi has to make sure that India becomes a highly competitive manufacturing hub where global investors will look to invest, the chairman of India...Asia Economyread more
The U.S. and Japan will likely reach a trade settlement in the next six to nine months that will "give each side something to claim credit for," says Glen Fukushima, former...World Economyread more
Bitcoin surged more than 9% from the day before to hit its highest level in more than a year.Technologyread more
Stocks in Asia were mixed Monday morning as investors watched for developments from U.S. President Donald Trump's state visit to Japan as well as results from the European...Asia Marketsread more
Sources say the talks have picked up speed in recent days and could lead to an announcement regarding a merger or partnership by Monday.Autosread more
Biden had criticized Kim Jong Un as a "dictator" and a "tyrant" at a recent rally in Philadelphia. North Korean state media responded by calling Biden a "fool of low IQ" among...Politicsread more
The U.S. Food and Drug Administration last week approved a drug made by Marathon Pharmaceuticals to treat Duchenne muscular dystrophy (DMD), a devastating muscle-wasting disease that mainly affects young boys.
The drug, Emflaza, known generically as deflazacort, belongs to a class of anti-inflammatory drugs known as corticosteroids that are frequently used to treat DMD and other conditions.
Emflaza is the first steroid to win formal FDA approval to treat DMD. Prednisone, another steroid, is frequently prescribed for the disease though it does not have official FDA approval. Emflaza is thought to have fewer side effects than Prednisone.
Deflazacort has been available outside the United States for decades.
The big issue facing closely held Marathon will be how to price the drug. Marathon did not invent deflazacort and patients have been able to import it inexpensively for personal use for years because there was not an approved U.S. treatment.
That will now change. Patients will no longer be allowed to import the drug now that an FDA-approved product is available. Northbrook, Illinois-based Marathon said the drug will carry a list price of $89,000 a year but that the company will provide a "robust" assistance program for patients who are not covered by insurance.
Duchenne's is a rare genetic disorder affecting some 15,000 U.S. patients that causes progressive muscle deterioration and kills most sufferers by the age of 30. Last year Dr. Janet Woodcock, head of the FDA's pharmaceuticals division, ordered the approval of a Duchenne drug made by Sarepta Therapeutics despite opposition from the agency's top scientists and a negative recommendation from a panel of outside advisers.
The FDA approved Emflaza for all DMD patients aged 5 and older. Sarepta's drug treats a subset of DMD patients representing about 13 percent of the total.
Sarepta's shares closed down 5.2 percent at $27.83 on Friday.